121,591 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 121,591 shares of the medical device company's stock, valued at approximately $3,716,000. Raymond James Financial Inc. owned approximately 0.25% of AtriCure as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP increased its holdings in shares of AtriCure by 0.4% during the third quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company's stock valued at $43,291,000 after acquiring an additional 6,045 shares in the last quarter. State Street Corp increased its stake in AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after purchasing an additional 63,002 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of AtriCure by 2.9% in the third quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock worth $32,326,000 after buying an additional 32,676 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of AtriCure by 14.6% during the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock worth $18,621,000 after buying an additional 84,700 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of AtriCure by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 399,428 shares of the medical device company's stock valued at $12,207,000 after buying an additional 4,844 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

AtriCure Stock Performance

Shares of ATRC traded up $0.43 during trading hours on Monday, hitting $32.26. The stock had a trading volume of 474,797 shares, compared to its average volume of 674,495. The firm has a 50-day moving average price of $37.85 and a 200 day moving average price of $34.06. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -33.96 and a beta of 1.53. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65.

Analysts Set New Price Targets

ATRC has been the subject of a number of research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $51.00 target price on shares of AtriCure in a research note on Thursday. Oppenheimer raised their price objective on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Canaccord Genuity Group dropped their target price on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday. BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday. Finally, Stifel Nicolaus lifted their price objective on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, AtriCure currently has an average rating of "Moderate Buy" and a consensus target price of $49.44.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is owned by company insiders.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.